Balancing Treatment and Risk: HBV Reactivation in RA Patients on JAK and IL-6 Inhibitors

by telrheum | Apr 23, 2024 | Biologic Therapy, Il-6 inhibitors, Infections, JAK Inhibitor

This article, “Risk of Hepatitis B Virus Reactivation in Patients with Rheumatoid Arthritis Receiving JAK Inhibitor or IL-6 Inhibitor: A Systematic Review and Meta-Analysis” by Akhil Sood, Janice Lin, and Neha Shah from Stanford University, presents a study that looks...

Rheumatic Medications: A New Frontier in Alzheimer’s Prevention?

by telrheum | Mar 12, 2024 | Biologic Therapy, JAK Inhibitor, Rheumatic Drugs

Recent studies have hinted at the intriguing possibility that certain drugs used in the treatment of rheumatic diseases might also have beneficial effects in preventing or delaying the development of Alzheimer’s disease. This article delves into the emerging...

Rinvoq: Truly Remarkable. The most proximate semblance to normality.

by telrheum | Mar 11, 2024 | JAK Inhibitor, Biologic Therapy, Colitis, Rheumatoid Arthritis, Spondyloarthritis

Rinvoq, a newer medication in the field of rheumatology and immunology, has shown remarkable efficacy in managing several chronic inflammatory conditions. As a selective Janus kinase (JAK) inhibitor, Rinvoq specifically targets pathways that contribute to the...

Xeljanz: Performance undeminished by Adaptation

by telrheum | Mar 11, 2024 | Rheumatoid Arthritis, Colitis, JAK Inhibitor

Xeljanz, known generically as tofacitinib, is a medication that represents a significant advancement in the treatment of various autoimmune diseases. Approved by the FDA, Xeljanz operates by inhibiting Janus kinase (JAK) pathways, which are crucial in the process of...